{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:57:05Z","timestamp":1792270625273,"version":"4.4.0"},"reference-count":61,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>The advent of biologic therapy for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) has allowed for substantial improvement in symptom control and reduction in medical resource utilization for patients with CRSwNP. CRSwNP is characterized by chronic symptoms (&gt;12\n weeks), including nasal congestion, hyposmia or anosmia, anterior or posterior mucopurulent drainage, and, in some patients, facial pain or pressure, with patients also having objective evidence of CRSwNP on nasal endoscopy or imaging. In Western countries, CRSwNP is most frequently marked\n by type 2 inflammatory cells and mediators, including tissue eosinophilia, T helper type 2 cells, group 2 innate lymphoid cells, locally produced immunoglobulin E, type 2 cytokines, and mast cell activation. Both CRSwNP and aspirin-exacerbated respiratory disease (AERD), an important, severe\n phenotype of CRSwNP, are associated with impairments in quality of life, medical resource consumption, and recurrent CRSwNP after functional endoscopic sinus surgery (FESS), with some patients requiring revision FESS. There are now four U.S. Food and Drug Administration approved biologics\n for treatment of CRSwNP, including dupilumab, omalizumab, mepolizumab, and tezepelumab, and more under investigation for the treatment of CRSwNP. Biologics have been shown to decrease nasal polyp size, improve sense of smell, reduce the need for systemic corticosteroids and FESS, and improve\n quality of life for patients with CRSwNP. In this review, I discuss guidelines for the treatment of CRSwNP and AERD in the biologic era, efficacy of biologic medications, and emerging real-world evidence for the use of biologic therapy for CRSwNP and AERD.<\/jats:p>","DOI":"10.2500\/aap.2026.47.260015","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:42:02Z","timestamp":1777437722000},"page":"162-169","source":"Crossref","is-referenced-by-count":2,"title":["The medical management of chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory in the biologic age"],"prefix":"10.2500","volume":"47","author":[{"given":"Kathleen M.","family":"Buchheit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International Consensus statement on allergy and rhinology: Rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaci.2025.03.011","article-title":"Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps","volume":"155","author":"Kratchmarov","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2021.12.030","article-title":"Controversies in allergy: aspirin desensitization or biologics for aspirin-exacerbated respiratory disease-how to choose","volume":"10","author":"Laidlaw","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaip.2023.12.016","article-title":"Efficacy of EDS-FLU for chronic rhinosinusitis: two randomized controlled trials (ReOpen1 and ReOpen2)","volume":"12","author":"Palmer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B8","first-page":"287","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"B9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/alr.22487","article-title":"Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors","volume":"10","author":"Loftus","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaci.2022.02.029","article-title":"Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps","volume":"150","author":"Bai","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/jcm13030866","article-title":"Long-term clinical outcomes in patients with chronic rhinosinusitis with nasal polyps associated with expanded types of endoscopic sinus surgery","volume":"13","author":"Martin-Jimenez","year":"2024","journal-title":"J Clin Med"},{"key":"B12","first-page":"239","article-title":"Remission in chronic rhinosinusitis with nasal polyps (CRSwNP)","volume":"63","author":"Hellings","year":"2025","journal-title":"Rhinology"},{"key":"B13","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.jaip.2024.09.021","article-title":"Efficacy of biologics in NSAID-ERD: united airways from the nose to the bronchi","volume":"12","author":"Buchheit","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/alr.22865","article-title":"Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease","volume":"11","author":"Yong","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"131","author":"Scangas","year":"2021","journal-title":"Laryngoscope"},{"key":"B16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/alr.22936","article-title":"Economic evaluation of dupilumab versus endoscopic sinus surgery for the treatment of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Parasher","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/19458924241298817","article-title":"Dupilumab treatment for aspirin-exacerbated respiratory disease in a real-world setting: impact on quality of life and healthcare utilization","volume":"39","author":"Mullur","year":"2025","journal-title":"Am J Rhinol Allergy"},{"key":"B18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/cea.14348","article-title":"Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization","volume":"53","author":"Buchheit","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"B19","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1016\/j.jaip.2025.08.032","article-title":"Addition of dupilumab for patients with aspirin-exacerbated respiratory disease who have poor response to aspirin therapy after desensitization","volume":"13","author":"Achanta","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41586-018-0449-8","article-title":"Allergic inflammatory memory in human respiratory epithelial progenitor cells","volume":"560","author":"Ordovas-Montanes","year":"2018","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/all.16189","article-title":"Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis","volume":"79","author":"Bachert","year":"2024","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months","volume":"78","author":"van der Lans","year":"2023","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1111\/all.16357","article-title":"More than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days","volume":"79","author":"Otten","year":"2024","journal-title":"Allergy"},{"key":"B26","first-page":"403","article-title":"Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP","volume":"62","author":"Otten","year":"2024","journal-title":"Rhinology"},{"key":"B27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2500\/aap.2023.44.230015","article-title":"Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis","volume":"44","author":"Peters","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jaip.2024.03.011","article-title":"Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease","volume":"12","author":"Brown","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/alr.23108","article-title":"Dupilumab-related adverse events among patients with chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Lee","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/lary.32205","article-title":"Sustained efficacy and low rate of adverse events of dupilumab in type-2 CRSwNP over 48 months","volume":"135","author":"Orlando","year":"2025","journal-title":"Laryngoscope"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5R\u03b1 marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.anai.2023.11.001","article-title":"Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status","volume":"132","author":"Gevaert","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"B39","first-page":"37","article-title":"Improvement in olfaction in patients with CRSwNP and severe asthma taking anti-IgE and anti-IL-5 biologics: a real-life study","volume":"33","author":"Barroso","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/all.16303","article-title":"Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: effects on and beyond eosinophils","volume":"79","author":"Buchheit","year":"2024","journal-title":"Allergy"},{"key":"B43","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B44","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/alr.23219","article-title":"Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up","volume":"14","author":"Desrosiers","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B46","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B49","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jaip.2025.03.033","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR","volume":"13","author":"Laidlaw","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B50","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B52","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.jaip.2024.09.015","article-title":"Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison","volume":"12","author":"Hopkins","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B53","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"B54","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jaip.2025.04.043","article-title":"Reappraisal of biologic efficacy from phase 3 trials in refractory chronic rhinosinusitis and nasal polyps","volume":"13","author":"Lipworth","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B55","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S2213-2600(25)00287-5","article-title":"Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial","volume":"13","author":"De Corso","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B56","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B58","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making","volume":"19","author":"Otten","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/alr.23466","article-title":"Switching biologics in chronic rhinosinusitis with nasal polyps: a multicenter Canadian experience","volume":"15","author":"Dorling","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"B60","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000003\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:44:30Z","timestamp":1782535470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,1]]}},"alternative-id":["1088-5412(20260501)47:3L.162;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260015","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}